With the complexities of contemporary healthcare systems and the paramount importance of high-quality patient care, Simulation-Based Medical Education (SBME) has emerged as a pivotal innovation in the process of training healthcare professionals. This study explores the integration of SBME in undergraduate medical education to bridge the gap between theoretical knowledge and clinical practice, thereby preparing students with the necessary competencies for effective healthcare delivery.
The Review type of an article
Among working-age adults, diabetes is a primary cause of visual impairment. Pan-retinal photocoagulation, the standard treatment for proliferative diabetic retinopathy, is effective but comes with well-established adverse effects, including limitations on the peripheral visual field. The mechanism of vascular proliferation is thought to be triggered by vascular endothelial growth factor (anti-VEGF). Anti-VEGF medications have been studied extensively in the treatment of diabetic macular edema, and the results suggest that treatment with anti-VEGF medications causes a decrease in diabetic retinopathy. Anti-VEGF therapies can be used to treat underlying proliferative diabetic retinopathy in cases of vitreous bleeding when platelet-rich plasma cannot be used, delaying, or reducing the necessity for a vitrectomy. However, the limitations of anti-VEGF therapy require careful patient selection and constant observation. Recent clinical trials and recommendations for the use of anti-VEGF in proliferative diabetic retinopathy are presented in this review
The term "hepatitis" implies liver damage by inflammatory cells, a condition with numerous origins. Viruses, predominantly hepatitis B and C viruses cause most cases of hepatitis, which can lead to chronic liver diseases. Assessing the general knowledge and awareness of the population regarding viral hepatitis is crucial for developing targeted and effective strategies to address these epidemics. This knowledge can help tailor interventions for different population strata, such as youth and adults, thereby enhancing the impact of prevention and care efforts.
Inhibitory hemophilia: contemporary treatment with emicizumab. Considerations for pediatric practice
This article provides an overview of current knowledge and global experience regarding the use of emicizumab, with a focus on its specific considerations in pediatric practice. Emicizumab, a monoclonal antibody, operates uniquely compared to other therapies. It has been approved in Moldova since 2019 for preventing bleeding in hemophilia patients. Significant data from clinical studies and accumulated clinical practice provide answers to most questions physicians have when prescribing emicizumab. The article presents recommendations based on current information and global experience to aid decision-making in emicizumab usage. The purpose of this article is to provide information on management tactics for pediatric patients with hemophilia A receiving emicizumab.
The article discusses oral lichen planus (OLP), a chronic inflammatory disease of unknown etiology characterized by recurrent lesions on the oral mucosa. Despite its prevalence, the exact causes and pathogenesis of OLP are not well understood, and current treatments often yield unsatisfactory results with potential adverse effects.
The article discusses pituitary neuroendocrine tumors, which represent a significant portion of central nervous system tumors, particularly in older adults. It highlights the lack of universal surgical approaches for these tumors, necessitating experienced surgeons for accurate management.